Analysed MOLECULIN BIOTECH INC (MBRX:NASDAQ) News Sources
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
13-05-2026
yahoo.com
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
15-05-2026
yahoo.com
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
21-05-2026
yahoo.com
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
29-05-2026
yahoo.com
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
04-06-2026
yahoo.com
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
05-06-2026
yahoo.com
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
30-06-2026
yahoo.com
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance
30-06-2026
stocktwits.com
What is the current price of MOLECULIN BIOTECH INC (MBRX:NASDAQ)?
The current price of MOLECULIN BIOTECH INC (MBRX:NASDAQ) is $1.36.
MOLECULIN BIOTECH INC (MBRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of MOLECULIN BIOTECH INC (MBRX:NASDAQ) since the previous trading day is $-0.83.
MOLECULIN BIOTECH INC (MBRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of MOLECULIN BIOTECH INC (MBRX:NASDAQ) since the previous trading day is -37.8995%.
What is the most recent average sentiment score for MOLECULIN BIOTECH INC (MBRX:NASDAQ)?
The most recent average sentiment score for MOLECULIN BIOTECH INC (MBRX:NASDAQ) is 57 out of 100.
What is the most recent average sentiment for MOLECULIN BIOTECH INC (MBRX:NASDAQ)?
The most recent sentiment for MOLECULIN BIOTECH INC (MBRX:NASDAQ) is .
SEC-8K** Filing Available For MOLECULIN BIOTECH INC (MBRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.